The scale of the investment at stake is considerable. Robotic surgery systems for joint replacement typically cost around one million pounds in upfront capital expenditure, with an additional estimated one thousand to two thousand five hundred pounds per patient in procedural costs. For a health service performing hundreds of thousands of hip and knee replacements each year, the difference between adopting robotics widely and continuing with conventional techniques represents a financial commitment running into billions of pounds. Against that backdrop, the researchers behind the new studies argue that their results highlight the importance of careful evaluation of robotic technology in publicly funded healthcare systems, given the substantially higher capital and procedural costs involved compared with established surgical methods.

Robotic-assisted joint replacement involves surgeons using computer-controlled robotic arms and high-definition camera systems to assist them during complex procedures. The technology is designed to help plan and execute bone cuts and implant positioning with a precision that exceeds what can be achieved freehand, and earlier studies have consistently shown that robotic assistance does improve the accuracy of implant placement. Better alignment and positioning have long been considered plausible routes to longer-lasting implants, since malpositioned components can wear unevenly, loosen, or destabilise a joint over time. If more precise surgery translated into fewer failed implants, the economics of robotics could eventually prove favourable even at a high initial price. What has remained unclear, however, is whether that theoretical chain of benefit actually holds in clinical practice.

That uncertainty prompted the National Institute for Health and Care Excellence, the body that advises the NHS on which technologies represent value for money, to call for urgent research into the effect of robotic surgery on revision risk after joint replacement. Revision surgery, in which a failed or problematic implant is replaced with a new one, is more complex, more costly, and generally associated with worse outcomes for patients than the original operation. Any technology that reliably reduced revision rates would therefore carry substantial clinical and economic value. The new studies were designed to answer precisely this question using the most comprehensive source of joint replacement data available in the United Kingdom.

The research team analysed National Joint Registry records covering 666,283 total hip replacements, of which 656,080 were performed conventionally and 10,203 robotically, and 697,145 total or partial knee replacements, of which 675,034 were conventional and 22,111 robotic. All procedures took place between 2018 and 2024 in both public and private hospitals across the UK, making this the first big data study of robotic joint replacement conducted in the country. Because patients are not randomly assigned to robotic or conventional surgery, the researchers used a statistical technique known as propensity score matching to balance out underlying differences between the two groups, allowing more reliable comparisons to be drawn from observational data.

Propensity score matching works by pairing patients who underwent robotic surgery with statistically comparable patients who had conventional operations, matching on characteristics that could independently influence outcomes. In this analysis, the factors taken into account included age, sex, body mass index, underlying diagnosis, physical fitness, implant type, and surgeon volume. By constructing balanced comparison groups in this way, the method seeks to mimic the conditions of a randomised controlled trial, an approach known as target trial emulation. The researchers note that this is one of the most robust methods available for analysing observational data, providing vital insights to help commissioners plan care when randomised evidence is not yet available.

Having constructed their matched cohorts, the researchers compared a broad range of outcomes between the robotic and conventional groups, including implant survival, patient survival, the specific reasons for revision surgery, and complications occurring during the operations themselves. Patients were followed for an average of two and a half years after surgery. The results were striking in their uniformity: there were no differences in implant survival, no differences in overall or cause-specific revision risk, and no differences in intraoperative complications between the robotic and conventional hip replacement groups, and the same pattern held for knee replacements. Nor was there any difference in patient survival between the conventional and robotic hip replacement cohorts.

There was one notable exception to the otherwise null findings. Robotic surgery was associated with a lower risk of hip revisions that may be related to implant malpositioning than conventional surgery. This result is consistent with the established finding that robotic systems improve the accuracy of component placement, and it suggests that the technology may indeed reduce the specific subset of failures attributable to imperfect positioning. However, because malpositioning accounts for only a fraction of all revision procedures, this advantage was not large enough to produce a detectable difference in overall revision rates or implant survival across the matched groups during the follow-up period.

The authors are careful to spell out the limitations of their work. These are observational studies, so no firm conclusions can be drawn about cause and effect, and other unmeasured factors could have influenced the findings despite the rigor of the matching process. The average follow-up of two and a half years is also relatively short in the context of joint implants, which are expected to last fifteen to twenty years or more in many patients, and the researchers acknowledge that this limited follow-up period may mask longer-term outcomes that could yet diverge between the two surgical approaches. Questions about patient functional outcomes, such as pain, mobility, and quality of life after surgery, also remain open, and these will be addressed in due course by the ongoing RACER clinical trials.

Even so, the immediate implications for health policy are difficult to ignore. With the NHS planning a sevenfold expansion of robotic surgery by 2035, the new evidence provides the first large-scale national test of whether that investment is justified by improved outcomes, and the answer so far is that it is not, at least for the endpoints of implant survival, revision risk, and surgical complications. The researchers conclude that the results underscore the importance of careful evaluation of robotic technology in publicly funded healthcare systems, given the substantially higher capital and procedural costs involved. Until longer-term data or the RACER trials demonstrate benefits that conventional surgery cannot match, the case for widespread adoption of robotics in hip and knee replacement remains, on this evidence, unproven.

Subject of Research: Comparison of robotic-assisted versus conventional hip and knee replacement surgery using UK National Joint Registry data

Article Title: Robotic surgery offers no clear benefit over conventional joint replacement surgery

Article References: Robotic surgery offers no clear benefit over conventional joint replacement surgery. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: robotic surgery, hip replacement, knee replacement, joint replacement, National Joint Registry, The BMJ, NHS, revision surgery, implant survival, propensity score matching, health technology assessment, surgical outcomes

The trial enrolled 292 patients with symptomatic knee osteoarthritis classified as Kellgren-Lawrence grade 0, 1 or 2 on X-ray, a scale that ranges from no definite visible disease to definite bone spurs with possible early narrowing of the joint space. Notably, even patients with grade 0 X-rays showed evidence of osteoarthritis on MRI, meaning the study captured disease at its earliest stages. Patients with advanced grade 3 and 4 disease were excluded, keeping the focus squarely on early to moderate disease. The participants were unusually young for an osteoarthritis study, with a median age of just 38 years, a detail that makes the long follow-up period particularly valuable for tracking how the disease evolves over decades of life.

Participants were randomly assigned at a single institution in Russia to one of two treatment arms. The control group received glucosamine and chondroitin, two widely used dietary supplements often prescribed for joint health. The experimental group received the same medications plus a course of low-dose radiation therapy totaling 4.5 Gray, delivered in 10 treatments using an orthovoltage machine that generates low-energy X-rays. That total dose is a small fraction of what is used to treat cancer, where curative regimens often exceed 40 to 60 Gray. The rationale for using radiation at such low doses rests on a well-documented biological phenomenon: while high doses kill cells, very low doses can suppress inflammatory signaling, modulating the chronic inflammation that drives cartilage breakdown in osteoarthritis.

The short-term results reinforced what earlier studies had suggested. Both groups reported less pain immediately after treatment, but only the radiation arm sustained that benefit over time. Patients who received radiation therapy also reported significantly greater and more durable improvements in physical function and quality of life than those treated with medication alone. Because osteoarthritis has no cure and conventional therapies such as exercise, weight management, medications and injections relieve symptoms without reliably slowing structural progression, a treatment that could alter the disease course would represent a genuine shift in the field.

The structural evidence came from MRI scans tracked for three years after treatment. At 12 months, imaging scores showed slight improvement among patients who received radiation therapy, while the medication-only group continued to worsen. The significant difference between the groups persisted throughout the follow-up period. This alignment between what patients felt and what the scanner saw is what makes the study stand out, according to study author Bobby (Nagendra) Koneru, MD, FASTRO, a radiation oncologist at Loyola University in Maywood, Illinois. In his view, the most compelling aspect is how the outcomes fit together: sustained improvement in pain and function, less joint deterioration on MRI, and years later, less disability and fewer knee replacements among patients with grade 2 disease.

The long-term outcomes came from regional health records examined over a median follow-up of 11.9 years. Across the entire study population, radiation therapy was associated with a statistically significant 67 percent lower adjusted hazard of government-certified disability due to knee osteoarthritis. Koneru emphasized that this endpoint reflects an independently certified consequence of knee disease rather than a subjective report, complementing the improvements seen in symptoms and imaging. Because disability certification in the Russian system involves an external government assessment, the finding is less vulnerable to the placebo effects that can inflate patient-reported outcomes in unblinded trials.

The most striking results emerged among the 78 patients with grade 2 disease, where osteoarthritis was established but not yet advanced. Disability developed in 31 percent of patients who received radiation therapy compared with 61 percent of those on medication alone, and knee replacement was performed in 14 percent versus 36 percent respectively. Both differences were statistically significant. Koneru suggested that grade 2 disease may represent a window in which osteoarthritis is present but extensive joint damage has not yet occurred, offering an opportunity to study whether treating inflammation earlier can change the longer course of the disease. Across the full study population, however, the difference in knee replacement rates did not reach statistical significance, a caveat the researchers acknowledged.

The study carries important limitations that temper enthusiasm. Participants knew whether they had received radiation, and the control group received medication rather than simulated radiation, leaving open the possibility that expectation effects contributed to the symptom improvements. The long-term outcomes and the grade 2 subgroup analyses were exploratory rather than pre-specified primary endpoints. Follow-up MRI data were incomplete, although the imaging readers were blinded to treatment assignment. The trial was also conducted at a single institution in Russia, and differences in health care delivery or access to knee replacement may limit how broadly the results apply to other populations and health systems.

Safety data were reassuring within the limits of the study design. No acute radiation reactions or cancers within the treated area were reported during follow-up. Low-dose radiation therapy has been used for decades in parts of Europe and increasingly in the United States to relieve pain from osteoarthritis and other noncancerous inflammatory conditions. Still, the study was not designed to quantify rare late effects or lifetime cancer risk, a particularly relevant question in a population with a median age of 38, and larger prospective studies will be needed to assess long-term safety alongside the durability of benefit.

Experts outside the study team see the findings as a reason to push the science forward rather than a reason to change practice immediately. Gopal K. Bajaj, MD, MBA, FASTRO, co-chair of ASTRO’s Functional Radiation Medicine Task Force and a radiation oncologist at Inova Schar Cancer Institute in Fairfax, Virginia, noted that osteoarthritis treatments can help patients feel better but that there is far less evidence they change what is happening inside the joint. What makes these findings interesting, he said, is that the patient-reported improvement was accompanied by a measurable difference on MRI, moving the question beyond pain relief alone, and the long-term disability data add another reason to test whether low-dose radiation can affect the course of early osteoarthritis in a larger, rigorously controlled trial. Koneru agreed, calling for a multicenter randomized trial using simulated radiation as the control, with prospectively defined imaging and long-term clinical endpoints and a focus on patients with grade 2 disease. If such a trial confirms these results, a therapy borrowed from the cancer clinic could become a disease-modifying option for one of the world’s most common causes of chronic pain and disability.

Subject of Research: Low-dose radiation therapy for knee osteoarthritis progression

Article Title: Low-dose radiation therapy may slow progression of knee osteoarthritis, long-term study indicates

Article References: Low-dose radiation therapy may slow progression of knee osteoarthritis, long-term study indicates. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: low-dose radiation therapy, knee osteoarthritis, randomized trial, cartilage deterioration, MRI imaging, disability prevention, knee replacement, inflammation, orthovoltage X-rays, ASTRO, Kellgren-Lawrence grade, disease-modifying treatment